Get to know our clinical trials

Clinical trial of lanifibranor in adult patients with nonalcoholic steatohepatitis without cirrhosis and stage 2/grade 3 liver fibrosis

THE AIM OF THIS STUDY IS TO SEE IF A DRUG NOT YET APPROVED BY ANY REGULATORY AUTHORITY FOR MARKETING, CALLED LANIFIBIBRANOR, WILL HELP IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) WITHOUT CIRRHOSIS AND LIVER FIBROSIS STAGE (THE AMOUNT OF SCARRING) GRADE 2 (F2)/GRADE 3(F3) AND IF IT IS SAFE TO USE IN PEOPLE.

Status
In recruitment
headquarters
Madrid

Technical Summary

  • PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LANIFIBRANOR IN ADULT PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) WITHOUT CIRRHOSIS AND LIVER FIBROSIS STAGE GRADE 2 (F2)/GRADE 3 (F3)
  • Code EudraCT: 2020-004986-38
  • Protocol number: 337HNAS20011
  • Promoter: Inventiva
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.